iCP-NI
/ Cellivery
- LARVOL DELTA
Home
Next
Prev
1 to 8
Of
8
Go to page
1
September 20, 2025
iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects
(clinicaltrials.gov)
- P1 | N=24 | Terminated | Sponsor: Cellivery Therapeutics, Inc. | N=64 ➔ 24 | Suspended ➔ Terminated; Closed by Sponsor for business reasons
Enrollment change • Trial termination
November 06, 2023
Intracellular delivery of nuclear localization sequence peptide mitigates COVID-19 by inhibiting nuclear transport of inflammation associated transcription factors.
(PubMed, Mol Ther)
- "Similarly, in hamsters infected with SARS-CoV-2, iCP-NI effectively protected the lung from inflammatory damage by reducing TNF-α, IL-6, and IL-17 levels. These promising results highlight iCP-NI's potential as a therapeutic approach for COVID-19-related lung complications and other inflammatory lung diseases."
Journal • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • IL17A • IL6 • TNFA
May 17, 2023
iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects
(clinicaltrials.gov)
- P1 | N=64 | Suspended | Sponsor: Cellivery Therapeutics, Inc. | Recruiting ➔ Suspended
Trial suspension
February 23, 2023
iCP-NI - Safety, Tolerability, Pharmacokinetic, and Immunogenicity Study in Healthy Male and Female Subjects
(clinicaltrials.gov)
- P1 | N=64 | Recruiting | Sponsor: Cellivery Therapeutics, Inc.
New P1 trial
April 08, 2022
Intracellularly Delivered Nuclear Localization Sequence Attenuates The Severity Of COVID-19 By Inhibits Interaction Of Inflammatory Transcription Factors And Importins
(IMMUNOLOGY 2022)
- "Likewise, the levels of inflammatory cytokines such as TNF-α and IL-17A in the lungs are significantly decreased and thereby, the lung structures are protected from inflammation-mediated damages. As a result, the iCP-NI could be developed as a novel medicine to cure various inflammatory diseases including COVID-19."
Acute Respiratory Distress Syndrome • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Pneumonia • Pulmonary Disease • Respiratory Diseases • IL17A • STAT1 • TNFA
April 08, 2022
Intracellular Delivery Of Nuclear Localization Signal Relieves Inflammatory Pulmonal Disease Through Regulating Immune System By Patient-Friendly Inhalant Formulation
(IMMUNOLOGY 2022)
- "Also, iCP-NI inhibited the recruitment of neutrophils (99.8%) and macrophages (99.6%) in BALF, and thereby induced the restoration of damaged lung tissue. In conclusion, iCP-NI has a significant therapeutic effect on COPD through immune system control and potential as a patient-friendly anti-inflammatory drug."
Clinical • Chronic Obstructive Pulmonary Disease • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • ELANE • IL6 • TNFA
February 23, 2021
Cellivery "Intrinsic Immune Control Inflammation Treatment, Formulation Completed by Indication" [Google translation]
(Hankyung)
- "Shelly discard...announced that it has signed a Euro-pin and 23 days of inhaled formulation formulation development and manufacturing contract with a global formulation foster professional development and production organizations (CDMO) Luxembourg. This is to develop...'iCP-NI' as a treatment for refractory autoimmune respiratory diseases."
Licensing / partnership • Crohn's disease • Immunology • Inflammatory Bowel Disease • Ulcerative Colitis
January 14, 2021
Cellivery announces the efficacy of anti-inflammatory drug iCP-NI on the treatment of autoimmune disease Soriasis at JPMorgan conference (Google translation)
(Pax Economic TV)
- "Cellibury (CEO Daewoong Cho) presented the latest research results of `iCP-NI, an autoimmune disease Soriasis (psoriasis) treatment' at the JPMorgan Healthcare Conference (JPMHC) in 2021 to global pharmaceutical companies on the 14th...'In the skin tissues of the Soriasys disease model, iCP-NI reduced the penetration of inflammation-inducing immune cells (T cells) into skin tissues by 80%'...'By reducing alpha (TNF-α) and interleukin-22 (IL-22) by 66% and 90%, respectively, it showed strong anti-inflammation and anti-psoriasis treatment effects.'"
Preclinical • Psoriasis
1 to 8
Of
8
Go to page
1